Kimberly E. Vanover

Intra-Cellular Therapies, Inc. operates as a biopharmaceutical company which focuses on the discovery and clinical development of innovative, small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system. The company's technology addresses diseases of the central nervous system, including schizophrenia, cognition, Parkinson's disease, anxiety, depression, Alzheimer's disease, sleep, and those related to women's health. Its products include clinical development plan for schizophrenia and unique mechanism of action. Intra-Cellular Therapies was founded by Paul Greengard, Sharon Mates and Allen A. Fienberg on May 22, 2001 and is headquartered in New York, NY.

CoCensys, Inc. discovers and develops drugs to treat neurological and psychiatric disorders. The company's product development programs focus on two novel and proprietary classes of compounds: Epalons, to treat epilepsy, migraine, anxiety and sleep disorders and Excitatory Amino Acid (EAA) receptor antagonists, to treat stroke, head trauma, epilepsy and Parkinson's disease. The company was founded in 1989 and is located in Irvine, CA.

Part of Pfizer Inc., Lederle Laboratories is a company that provides testing services. The company is based in Pearl River, NY.